Michael J. La Barre is SVP, CHIEF TECHNICAL OFFICER of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 173,756 shares of HALO, which is worth approximately $11.3 Million. The most recent transaction as insider was on Feb 10, 2024, when has been sold 8,133 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 174K
0% 3M change
10.99% 12M change
Total Value Held $11.3 Million

Michael J. LaBarre Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 10 2024
BUY
Exercise of conversion of derivative security
-
8,133 Added 4.84%
160,044 Common Stock
Jan 17 2024
SELL
Open market or private sale
$360,000 $36.0 p/Share
10,000 Reduced 6.18%
151,911 Common Stock
Jan 17 2024
BUY
Exercise of conversion of derivative security
$120,700 $12.07 p/Share
10,000 Added 5.82%
161,911 Common Stock
Jan 16 2024
SELL
Open market or private sale
$360,000 $36.0 p/Share
10,000 Reduced 6.18%
151,911 Common Stock
Jan 16 2024
BUY
Exercise of conversion of derivative security
$120,700 $12.07 p/Share
10,000 Added 5.82%
161,911 Common Stock
Dec 13 2023
SELL
Open market or private sale
$403,900 $40.39 p/Share
10,000 Reduced 6.18%
151,911 Common Stock
Dec 13 2023
BUY
Exercise of conversion of derivative security
$120,700 $12.07 p/Share
10,000 Added 5.82%
161,911 Common Stock
Dec 12 2023
SELL
Open market or private sale
$400,300 $40.03 p/Share
10,000 Reduced 6.18%
151,911 Common Stock
Dec 12 2023
BUY
Exercise of conversion of derivative security
$129,400 $12.94 p/Share
10,000 Added 5.82%
161,911 Common Stock
Nov 15 2023
SELL
Open market or private sale
$397,900 $39.79 p/Share
10,000 Reduced 6.18%
151,911 Common Stock
Nov 15 2023
BUY
Exercise of conversion of derivative security
$138,100 $13.81 p/Share
10,000 Added 5.82%
161,911 Common Stock
Nov 14 2023
SELL
Open market or private sale
$390,800 $39.08 p/Share
10,000 Reduced 6.18%
151,911 Common Stock
Nov 14 2023
BUY
Exercise of conversion of derivative security
$153,000 $15.3 p/Share
10,000 Added 6.11%
153,619 Common Stock
Oct 17 2023
SELL
Open market or private sale
$365,200 $36.52 p/Share
10,000 Reduced 6.18%
151,911 Common Stock
Oct 17 2023
BUY
Exercise of conversion of derivative security
$199,800 $19.98 p/Share
10,000 Added 5.82%
161,911 Common Stock
Sep 19 2023
SELL
Open market or private sale
$391,000 $39.1 p/Share
10,000 Reduced 6.18%
151,911 Common Stock
Sep 19 2023
BUY
Exercise of conversion of derivative security
$199,800 $19.98 p/Share
10,000 Added 5.82%
161,911 Common Stock
Aug 22 2023
SELL
Open market or private sale
$424,099 $42.41 p/Share
10,000 Reduced 6.18%
151,911 Common Stock
Aug 22 2023
BUY
Exercise of conversion of derivative security
$192,000 $19.2 p/Share
10,000 Added 5.88%
159,986 Common Stock
Jul 18 2023
SELL
Open market or private sale
$404,300 $40.43 p/Share
10,000 Reduced 6.58%
141,911 Common Stock
Jul 18 2023
BUY
Exercise of conversion of derivative security
$268,800 $13.44 p/Share
20,000 Added 11.63%
151,911 Common Stock
Jun 21 2023
SELL
Open market or private sale
$360,000 $36.0 p/Share
10,000 Reduced 6.58%
141,911 Common Stock
Jun 21 2023
BUY
Exercise of conversion of derivative security
$184,100 $18.41 p/Share
10,000 Added 6.18%
151,911 Common Stock
Apr 18 2023
SELL
Open market or private sale
$360,000 $36.0 p/Share
10,000 Reduced 6.58%
141,911 Common Stock
Apr 18 2023
BUY
Exercise of conversion of derivative security
$184,100 $18.41 p/Share
10,000 Added 6.18%
151,911 Common Stock
MJL

Michael J. La Barre

SVP, CHIEF TECHNICAL OFFICER
San Diego, CA

Track Institutional and Insider Activities on HALO

Follow HALOZYME THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO